Last Updated: 2026-03-15 PT
Cerebral amyloid angiopathy (CAA) is a critical comorbidity in Alzheimer's disease characterized by amyloid-beta (Aβ) deposition in the walls of cerebral blood vessels. CAA affects approximately 30-50% of AD patients and significantly impacts disease progression, treatment safety, and clinical outcomes. The intersection of CAA and AD represents a major knowledge gap with direct implications for therapeutic development, as anti-amyloid therapies carry significant risk in this population.
Gap: How does vascular Aβ deposition interact with parenchymal plaque formation?
Despite extensive research, the relationship between CAA and AD core pathology remains unclear:
- Does CAA drive Aβ plaque formation or vice versa?
- What determines whether Aβ deposits in vessels versus brain parenchyma?
- How does perivascular drainage failure contribute to both CAA and plaque accumulation?
Current hypotheses:
- Drainage competition: Aβ cleared via perivascular pathways may be shunted toward vascular deposition when one pathway fails
- Vascular production: Smooth muscle cells may produce Aβ locally, contributing to CAA
- Shared clearance impairment: Glymphatic dysfunction affects both parenchymal and vascular Aβ clearance
Gap: What is the relative contribution of CAA versus AD pathology to vascular cognitive impairment?
Patients with CAA-AD comorbidity often present with mixed dementia syndromes, but the relative contributions of:
- Small vessel disease burden (white matter hyperintensities, lacunes)
- Amyloid-related imaging abnormalities (ARIA)
- Co-existing AD neurodegeneration (tau pathology, neuronal loss)
- Cerebral hypoperfusion due to vessel wall thickening
...remain poorly quantified. Recent studies suggest CAA contributes independently to cognitive decline beyond AD pathology alone.
Gap: Can we develop better biomarkers to predict amyloid-related imaging abnormalities (ARIA)?
Anti-amyloid therapeutics (lecanemab, donanemab) carry significant ARIA risk:
- ARIA-E: Amyloid-related imaging abnormalities - edema/effusions (cortical swelling, FLAIR hyperintensity)
- ARIA-H: Amyloid-related imaging abnormalities - hemorrhages (microbleeds, cortical superficial siderosis)
Current risk stratification relies on:
- APOE ε4 carrier status (higher risk with ε4/ε4)
- Baseline microhemorrhage burden (≥4 microbleeds = higher risk)
- White matter hyperintensity load
- Prior cerebral hemorrhage history
Needed: Predictive biomarkers for ARIA susceptibility including:
- CSF/ plasma Aβ40/Aβ42 ratios as vascular amyloid markers
- Advanced MRI metrics (vessel wall imaging, permeability measures)
- Genetic panels beyond APOE
Gap: What is the role of perivascular Aβ clearance in both CAA and AD?
The glymphatic system and perivascular drainage pathways are implicated in:
- Aβ clearance from brain interstitial fluid
- CAA development when clearance fails
- Potential therapeutic targets for enhancing clearance
Key questions:
- How does aging affect perivascular clearance efficiency?
- Can glymphatic function be enhanced pharmacologically?
- What is the relationship between sleep-dependent glymphatic activation and CAA?
¶ 5. CAA Staging and Progression
Gap: Can we develop CAA-specific biomarkers for staging and progression?
Current CAA diagnosis relies on:
- MRI biomarkers (cortical superficial siderosis, lobar microhemorrhages, white matter lesions)
- PET imaging with amyloid PET tracers (Pittsburgh compound B, florbetapir)
- CSF biomarkers (decreased Aβ42/40 ratio as both vascular and parenchymal marker)
- Dynamic susceptibility contrast MRI for vessel function
Needed: Longitudinal biomarkers tracking CAA progression independently of AD:
- Vascular amyloid PET ligands with specificity for CAA
- CSF biomarkers that distinguish vascular from parenchymal Aβ
- MRI-based metrics of perivascular clearance
Gap: How should anti-amyloid therapy be modified in patients with CAA?
Key questions remain:
- Dose adjustment strategies: Should dosing be reduced in CAA patients?
- Monitoring protocols: Optimal MRI frequency and sequence for ARIA detection
- Contraindication thresholds: When should anti-amyloid therapy be avoided entirely?
- Combination approaches: Targeting both vascular and parenchymal Aβ simultaneously
- Alternative targets: Focus on tau or other targets when Aβ therapy is contraindicated
Gap: What makes Aβ deposit in cerebral vessels rather than brain parenchyma?
Current understanding:
- Aβ40 preferentially deposits in vessels ( CAA-predominant)
- Aβ42 preferentially deposits as plaques (AD-predominant)
- Vascular Aβ has distinct post-translational modifications
- Perivascular drainage efficiency varies between individuals
Needed: Understanding the molecular determinants of vascular vs. parenchymal Aβ aggregation to enable compartment-selective targeting.
| Dimension |
Score |
Rationale |
| Impact if Solved |
9 |
ARIA risk limits anti-amyloid therapeutic utility in ~30-50% of AD patients |
| Tractability |
6 |
Requires specialized MRI protocols, PET imaging, and longitudinal cohorts |
| Under-exploration |
8 |
CAA often treated as AD comorbidity rather than independent therapeutic target |
| Data Availability |
7 |
Existing ARIA trials, CAA consortia, and imaging biobanks provide foundation |
Total Score: 30 (Tier 1)
- Mechanistic: What determines Aβ deposition compartment (vascular vs. parenchymal)?
- Biomarker: Can we develop CAA-specific progression biomarkers?
- Clinical: How do we risk-stratify ARIA in CAA-AD patients for anti-amyloid therapy?
- Therapeutic: What are optimal monitoring and dose-adjustment strategies?
- Basic Science: What is the relationship between glymphatic dysfunction and CAA progression?
- Vessel wall MRI: New techniques to visualize leptomeningeal and cortical vessel inflammation in CAA
- Perivascular clearance quantification: MRI-based glymphatic flow measurements in CAA patients
- APOE isoform effects: Differential impact of APOE ε2 and ε4 on CAA progression and ARIA risk
- Anti-amyloid dosing studies: Population pharmacokinetic models for ARIA prediction
- CAA animal models: New models replicating human CAA pathology for therapeutic testing